Dear Colleagues,

It is our pleasure to invite you to the 4th International Conference on Lymphocyte Engineering, set to take place on 12 – 14 September 2023 in Munich, Germany.

Great strides have been made in recent years in the engineering of lymphocytes for the treatment of cancer, autoimmune diseases, pathogenic diseases, and primary immune deficiencies. Combining gene therapy, cell therapy and immune therapy, the emerging field of lymphocyte engineering employs cutting-edge technologies of viral and non-viral vectorology, genome editing, and protein design as well as advanced clinical protocols for cell harvest, expansion, and re-infusion and for the exciting alternative of in vivo engineering. With groundbreaking clinical success leading to FDA-approved products and with vibrant, exponentially growing research, lymphocyte engineering is the wave of the future.

Still, the challenges are formidable and the stakes are high. Realizing the full promise of lymphocyte engineering will require the combined efforts of a dedicated community. ICLE 2023 will facilitate the sharing of data and ideas, promote collaborations, and address common challenges to advance clinical translation. It will provide an effective environment for active learning, discussions of real-world case studies, and networking between like-minded peers.

Whether you are a scientist, clinical researcher, part of a start-up, or an established industry company, ICLE 2023 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality.

Please click here to register.

Abstract Submission is now open. The deadline to submit an abstract during this session is on Wednesday, 22 March 2023, at Midnight CET.

Looking forward to welcoming you to ICLE 2023!